- In July 2026, Sekisui Chemical Co., Ltd. updated its first-half fiscal 2026 guidance, slightly raising projected net sales to ¥690,500 million and operating profit to ¥48,000 million, while keeping profit attributable to owners of parent broadly unchanged, and also issued full-year 2026–27 guidance that includes expected net sales of ¥1.41 trillion and operating profit of ¥115,000 million.
- The guidance revision highlights how higher raw material and parts costs are being largely offset by sales price improvements and a weaker yen, offering investors insight into Sekisui Chemical’s current pricing power and cost management.
- We’ll now look at how Sekisui Chemical’s ability to offset higher input costs through pricing and currency tailwinds feeds into its investment narrative.
Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
Sekisui Chemical Investment Narrative Recap
Sekisui Chemical’s appeal rests on its mix of housing, infrastructure, specialty plastics, and medical businesses, all tied to long term needs like sustainability and aging populations. The latest guidance tweak, which shows higher first half sales and operating profit but unchanged bottom line, does not materially shift the near term picture. It does, however, put a spotlight on the biggest short term swing factor right now: how well Sekisui can manage raw material inflation and currency volatility.
Against that backdrop, the ongoing share buyback program is especially relevant. With authorization to repurchase up to 4,000,000 shares for ¥12,000 million through March 2027, buybacks and slightly higher dividend guidance frame how management is balancing reinvestment with shareholder returns, even as input costs rise. For investors focused on catalysts, this capital return policy now sits alongside pricing power and FX as a key part of the Sekisui story.
Yet even with these positives, the company’s sensitivity to input cost spikes and currency moves is something investors should be aware of if...
Read the full narrative on Sekisui Chemical (it's free!)
Sekisui Chemical's narrative projects ¥1,520.1 billion revenue and ¥95.0 billion earnings by 2029. This requires 5.1% yearly revenue growth and about a ¥19.8 billion earnings increase from ¥75.2 billion today.
Uncover how Sekisui Chemical's forecasts yield a ¥2606 fair value, a 3% downside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already cautious, assuming only about 4.2% annual revenue growth and earnings near ¥95,000 million by 2029, and this latest cost driven guidance tweak might either reinforce their concerns about margin pressure or prompt a rethink of how resilient Sekisui’s pricing power and cost control really are.
Explore another fair value estimate on Sekisui Chemical - why the stock might be worth as much as ¥2808!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Sekisui Chemical research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Sekisui Chemical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sekisui Chemical's overall financial health at a glance.
Looking For Alternative Opportunities?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com